The DOI matches its Crossref record; 146 of the 146 references it cites were found in a registry or an index.
Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM
Open accessAbstract
BACKGROUND: The European Atherosclerosis Society–European Federation of Clinical Chemistry and Laboratory Medicine Consensus Panel aims to provide recommendations to optimize atherogenic lipoprotein quantification for cardiovascular risk management. CONTENT: We critically examined LDL cholesterol, non-HDL cholesterol, apolipoprotein B (apoB), and LDL particle number assays based on key criteria for medical application of biomarkers. (a) Analytical performance: Discordant LDL cholesterol quantification occurs when LDL cholesterol is measured or calculated with different assays, especially in patients with hypertriglyceridemia >175 mg/dL (2 mmol/L) and low LDL cholesterol concentrations <70 mg/dL (1.8 mmol/L). Increased lipoprotein(a) should be excluded in patients not achieving LDL cholesterol goals with treatment. Non-HDL cholesterol includes the atherogenic risk component of remnant cholesterol and can be calculated in a standard nonfasting lipid panel without additional expense. ApoB more accurately reflects LDL particle number. (b) Clinical performance: LDL cholesterol, non-HDL cholesterol, and apoB are comparable predictors of cardiovascular events in prospective population studies and clinical trials; however, discordance analysis of the markers improves risk prediction by adding remnant cholesterol (included in non-HDL cholesterol) and LDL particle number (with apoB) risk components to LDL cholesterol testing. (c) Clinical and cost-effectiveness: There is no consistent evidence yet that non-HDL cholesterol-, apoB-, or LDL particle-targeted treatment reduces the number of cardiovascular events and healthcare-related costs than treatment targeted to LDL cholesterol. SUMMARY: Follow-up of pre- and on-treatment (measured or calculated) LDL cholesterol concentration in a patient should ideally be performed with the same documented test method. Non-HDL cholesterol (or apoB) should be the secondary treatment target in patients with mild to moderate hypertriglyceridemia, in whom LDL cholesterol measurement or calculation is less accurate and often less predictive of cardiovascular risk. Laboratories should report non-HDL cholesterol in all standard lipid panels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Calculated by subtracting HDLC from TC, non-HDLC represents the cholesterol in all particles causing cardiovascular disease, that is, LDL, VLDL, IDL, and Lp(a); in the nonfasting state this additionally includes the cholesterol in chylomicrons and their remnant particles [1].”
From Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM (2020) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It should be noted that most clinical trials demonstrating the evidence base for clinical benefit of LDLC lowering have used Friedewald cLDLC; thus it cannot be excluded that dLDLC rather than cLDLC is the method that misclassifies risk [1].”
From Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM (2020) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although apoB demonstrates competitive clinical performance compared with non-HDLC, there is no evidence yet of significant population healtheconomic benefit of intensifying pharmacological intervention aiming to further reduce apoB at very low concentrations of LDLC [1].”
From Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM (2020) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This may compensate for the under-or overestimation of LDLC in terms of clinical decision making, given the uncertainty of dLDLC measurements or the Friedewald calculation in dyslipidemic samples when LDLC lowering approaches 1.4 mmol/L, and non-HDLC can be used at high TG ≥ 4.5 mmol/l.”
From Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM (2020) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For the present purposes, the combination of non-HDLC with Martin-Hopkins cLDLC may be considered as an appropriate strategy to guide therapy and they can be calculated from the standard lipid profile [1].”
From Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM (2020) · cites this paper as [1]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Taken together with the evidence that apoB can be measured more accurately, more precisely, and more selectively than LDL-C or non-HDL-C,1,29–31”
From Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention (2024) · cites this paper as [29]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“RemnantC, measured or calculated, differs from non-HDLC in that non-HDLC contains RemnantC plus LDLC and does not differentiate between these two causal risk factors [1].”
From Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM (2020) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Direct LDLC measurement should preferably be used in the calculation of RemnantC; otherwise RemnantC simply equals TG/2.2 (in mmol/L) when Friedewald-calculated LDLC is used, i.e.TC -HDLC -(TC -HDLC -TG/2.2),and it does not add clinical information beyond TG concentration [1]”
From Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM (2020) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Not uncommonly, changes in a patient's LDLC test result over time are within the range of uncertainty of laboratory method variation and may not be due to therapeutic intervention [1].”
From Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM (2020) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Guideline-recommended therapeutic goals for non-HDLC are arbitrarily set typically at 0.8 mmol/L (30 mg/dL) higher than LDLC goals (Table 6); this value is based on the assumption that the”
From Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM (2020) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Thus, even when cross-reactivity of immunoassays to apoB48 occurs in nonfasting measurements, apoB quantification is essentially an estimate of LDL particle number if TG and Lp(a) concentrations are low [1].”
From Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM (2020) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Guideline-based non-HDLC thresholds have been arbitrarily defined by consensus of expert groups, based on the assumption that a normal VLDLC concentration exists when TG are < 1.7 mmol/L, which is < 0.8 mmol/L as estimated by the Friedewald formula [1,2].”
From Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM (2020) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Given the uncertainty of measurements and calculations of LDLC across different methods and laboratories, in hypertriglyceridemic patients the decision thresholds may not always be assumed to be universally applicable [1].”
From Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM (2020) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“However, the compromised accuracy of dHDLC assays in samples with hypertriglyceridemia reduces the benefit in reporting non-HDLC in some individuals in whom an apoB or LDLP measurement may be clinically useful [1].”
From Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM (2020) · cites this paper as [1]
In the citing paper
“Non-fasting TG is equivalent, if not superior, to fasting TG in assessing potential ASCVD risk.78,79”
In the citing paper
“However, this study [77] and another based on the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) trial [78] have shown that large absolute changes in Lp(a) may be needed to produce a clinically meaningful reduction in the risk of ASCVD events.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [78]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx144 · Cited by 3,962
Self-citationStone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.002 · Cited by 3,845
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296
Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871
Lipoprotein(a) as a cardiovascular risk factor: current status
Nordestgaard, B. G., Chapman, M. J., Ray, K., Borén, J., Andreotti, F., Watts, G. F., Ginsberg, H., Amarenco, P., Catapano, A., Descamps, O. S., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq386 · Cited by 1,807
Self-citation
Cited by
Sorted by citations
Items 101–200 of 259
Forte, F., Calcaterra, I. L., Lupoli, R., Orsini, R. C., Chiurazzi, M., Tripaldella, M., Iannuzzo, G., & Minno, M. N. D. D. (2020) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaa029 · Cited by 13
Langlois, M. R., Nordestgaard, B. G., Langsted, A., Chapman, M. J., Aakre, K. M., Baum, H. H. E., Borén, J., Bruckert, É., Catapano, A. L., Cobbaert, C. M., et al. (2021) · Laboratory Service · doi:10.17116/labs20211001145 · Cited by 13
Self-citationSolnica, B., Sniderman, A. D., Wyszomirski, A., Rutkowski, M., Chlebus, K., Bandosz, P., Pencina, M. J., & Zdrojewski, T. (2023) · International Journal of Cardiology · doi:10.1016/j.ijcard.2023.131150 · Cited by 12
Colivicchi, F., Fusco, S. A. D., Arca, M., Leggio, M., Caldarola, P., Murrone, A., Valente, S., Urbinati, S., Roncon, L., Amodeo, V., et al. (2021) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001175 · Cited by 13
Perfil lipoproteico avanzado en individuos con metabolismo glucémico normal y alterado
Puig-Jové, C., Castelblanco, E., Falguera, M., Hernández, M., Soldevila, B., Julián, M. T., Teis, A., Julve, J., Barranco-Altirriba, M., Franch‐Nadal, J., et al. (2021) · Revista Española de Cardiología · doi:10.1016/j.recesp.2021.02.013 · Cited by 14
Sniderman, A. D. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.05.010 · Cited by 12
Martínez‐Morillo, E., García-García, M., Concha, M. A. L., & Rello, L. (2020) · Biochemia Medica · doi:10.11613/bm.2021.010701 · Cited by 12
Borén, J., Packard, C. J., Nordestgaard, B. G., & Catapano, A. L. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf214 · Cited by 12
Self-citationBriers, P.-J., & Langlois, M. R. (2022) · University of Zagreb University Computing Centre (SRCE) · Cited by 11
Self-citationRemnant cholesterol, vascular risk, and prevention of atherosclerosis
Pintó, X., Fanlo‐Maresma, M., Esteve-Luque, V., & Millán, J. (2023) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2023.07.005 · Cited by 13
Ruhaak, L. R., Smit, N. P. M., Suchiman, H. E. D., Pieterse, M., Romijn, F. P. H. T. M., Beekman, M., & Cobbaert, C. M. (2018) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2018-0782 · Cited by 11
Self-citationLipoprotein(a) – Marker for cardiovascular risk and target for lipoprotein apheresis
Klingel, R., Heigl, F., Schettler, V. J. J., Roeseler, E., Grützmacher, P., Hohenstein, B., Vogt, A., Fassbender, C., Heibges, A., & Julius, U. (2019) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2019.08.037 · Cited by 11
Fanlo‐Maresma, M., Candás‐Estébanez, B., Esteve-Luque, V., Padró‐Miquel, A., Escrihuela-Vidal, F., Carratini-Moraes, M., Corbella, E., Corbella, X., & Pintó, X. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10102218 · Cited by 11
Advanced lipoprotein profile in individuals with normal and impaired glucose metabolism
Puig-Jové, C., Castelblanco, E., Falguera, M., Hernández, M., Soldevila, B., Julián, M. T., Teis, A., Julve, J., Barranco-Altirriba, M., Franch‐Nadal, J., et al. (2021) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2021.02.006 · Cited by 13
Remnant cholesterol: a reliable prognostic marker?
Pirillo, A., & Catapano, A. L. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad107 · Cited by 11
Self-citationLow prevalence of testing for apolipoprotein B and lipoprotein (a) in the real world
Murdock, D. J., Moll, K., Sanchez, R. J., Gu, J., Fazio, S., Geba, G. P., & Rodríguez, F. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100721 · Cited by 10
Pintó, X., Masana, L., Civeira, F., Fernández‐Real, J. M., Ibarretxe, D., Candás‐Estébanez, B., Puzo, J., Díaz-Díaz, J. L., Amigó, N., Esteban, M., et al. (2020) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2020.04.004 · Cited by 11
Koeder, C., Alzughayyar, D., Anand, C., Kranz, R., Husain, S., Schoch, N., Hahn, A., & Englert, H. S. (2022) · Obesity Science & Practice · doi:10.1002/osp4.649 · Cited by 10
Zubirán, R., Vargas‐Vázquez, A., Razo-Olvera, F. M. D., Cruz‐Bautista, I., Martagón, A. J., Sampson, M. L., Remaley, A. T., & Aguilar-Salinas, C. A. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.117364 · Cited by 10
Self-citationReijnders, E., van der Laarse, A., Ruhaak, L. R., & Cobbaert, C. M. (2024) · Clinical Proteomics · doi:10.1186/s12014-024-09465-w · Cited by 10
Self-citationSoran, H., Ho, J. H., Adam, S., & Durrington, P. N. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000614 · Cited by 10
Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose – 2025
Rached, F. H., Miname, M. H., Rocha, V. Z., Zimerman, A., Cesena, F. Y., Sposito, A. C., Santos, R. D., Behr, P. E. B., Bianco, H. T., Alves, R. J., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250640 · Cited by 42
Zafar, M., Mirza, M. R., Awan, F. R., Tahir, M., Sultan, R., Hussain, M., Ahmed, B., Abbas, S., Larsen, M. R., Choudhary, M. I., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-02211-4 · Cited by 11
Efficacy and safety of icosapent ethyl in hypertriglyceridaemia: a recap
Parhofer, K. G., Chapman, M. J., & Nordestgaard, B. G. (2020) · European Heart Journal Supplements · doi:10.1093/eurheartj/suaa116 · Cited by 11
Self-citationHataysal, E. P., Körez, M. K., Yeşildal, F., & İşman, F. K. (2024) · Clinica Chimica Acta · doi:10.1016/j.cca.2024.117853 · Cited by 8
Quality Assurance for Multiplex Quantitative Clinical Chemistry Proteomics in Large Clinical Trials
Reijnders, E., Romijn, F. P. H. T. M., Arslan, F., Georges, J. J. J., Pieterse, M., Schipper, E. R., Didden-Buitendijk, S., Martherus-Bultman, M. C., Smit, N. P. M., Diederiks, N. M., et al. (2024) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfae092 · Cited by 8
Self-citationLipoprotein cholesterol ratios and cardiovascular disease risk in US adults: a cross-sectional study
Yang, X., Chen, Q., Zhang, Q., & Yu, Z. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1529223 · Cited by 10
Shin, S., Kim, Y., Choe, Y., Kim, S. H., Cho, J., Kim, C., & Kim, K. (2025) · Environmental Health · doi:10.1186/s12940-025-01185-4 · Cited by 8
ApoC-III as Therapeutic Target: Is it Primetime for Clinical Use?
Biolo, M., Galimberti, F., Portinari, C., Bertocco, S., Tosin, P., Casula, M., Previato, L., Zambon, S., Simioni, P., & Zambon, A. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01315-w · Cited by 9
Repeated measurement of lipoprotein(a): technical versus biological variability
Koller, A., Pfurtscheller, C., Kheirkhah, A., Stark, K. J., Zimmermann, M. E., Heid, I. M., & Kronenberg, F. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120456 · Cited by 8
Self-citationCoremans, C., Delporte, C., COTTON, F. J., van de Borne, P., Boudjeltia, K. Z., & Antwerpen, P. V. (2021) · Molecules · doi:10.3390/molecules26175264 · Cited by 8
The role of atherogenic lipoproteins in diabetes: Molecular aspects and clinical significance
Banerjee, Y., Patti, A. M., Giglio, R. V., Ciaccio, M., Vichithran, S., Faisal, S., Stoian, A. P., Rizvi, A. A., & Rizzo, M. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108517 · Cited by 8
Daghistani, H., Hegazy, G. A., Alkhalofah, M., Alsobeihy, A., Nasser, S., Gad, H., Shamrani, T., Mufrrih, M., & Alyousfi, D. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02605-7 · Cited by 8
Rajtar-Salwa, R., Bobrowska, B., Socha, S., Dziewierz, A., Siudak, Z., Batko, J., Bartuś, S., & Krawczyk‐Ożóg, A. (2024) · Medicina · doi:10.3390/medicina60071124 · Cited by 10
Kim, Y., Shin, S., Choe, Y., Cho, J., Kim, C., Kim, S. H., & Kim, K. (2024) · Environmental Health · doi:10.1186/s12940-024-01144-5 · Cited by 7
Factors associated with oxidative stress status in pediatric patients with type 1 diabetes mellitus
Kacarevic, D., Bogavac‐Stanojević, N., Spasojević‐Kalimanovska, V., Bojanin, D., Milenković, T., Stefanović, A., Mihajlović, M., Vujčić, S., Vuković, R., Zeljković, A., et al. (2020) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2019-0555 · Cited by 7
The Truth About Fish (Oil) in the Treatment of Dyslipidemia
Pitha, J. V., & Poledne, R. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00904-9 · Cited by 7
Hypertriglyceridemia, a causal risk factor for atherosclerosis, and its laboratory assessment
Wieczorek, E., Ćwiklińska, A., & Jankowski, M. (2022) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2022-0189 · Cited by 7
Naser, A., Isgandarov, K., Güvenç, T. S., Güvenç, R. Ç., & Şahin, M. (2022) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20210641 · Cited by 7
Heidemann, B. E., Koopal, C., van Lennep, J. E. R., Stroes, E. S. G., Riksen, N. P., Mulder, M. T., van der Zee, L. C. V. V. –., Blackhurst, D., Visseren, F. L. J., & Marais, A. D. (2022) · Clinica Chimica Acta · doi:10.1016/j.cca.2022.11.035 · Cited by 7
Ephraim, R. K. D., Ativi, E., Ashie, S. A., Abaka‐Yawson, A., & Darkwah, K. O. (2023) · Bulletin of the National Research Centre/Bulletin of the National Research Center · doi:10.1186/s42269-023-01046-5 · Cited by 7
Evolving concepts on the management of dyslipidaemia
Descamps, O. S., Verhaegen, A. A., Demeure, F., Langlois, M. R., Rietzschel, E. R., Mertens, A. C., SUTTER, J. D., Wallemacq, C. M., Lancellotti, P., & Backer, G. D. (2019) · Acta Clinica Belgica · doi:10.1080/17843286.2019.1702823 · Cited by 7
Self-citationReijnders, E., Bossuyt, P. M., Jukema, J. W., Ruhaak, L. R., Romijn, F. P. H. T. M., Szarek, M. J., Trompet, S., Bhatt, D. L., Bittner, V., Díaz, R., et al. (2025) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.124.322336 · Cited by 6
Self-citationRentería, M. A., McClure, L. A., CALLAS, P. W., LaBode-Richman, V. M., Kroll, D. S., Manly, J. J., Zakai, N. A., Unverzagt, F. W., & Cushman, M. (2023) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2023.102170 · Cited by 6
Paz‐Graniel, I., García-Gavilán, J. F., Ros, E., Connelly, M. A., Babió, N., Mantzoros, C. S., & Salas‐Salvadó, J. (2023) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2023.11.003 · Cited by 8
Self-citationYang, P., Tang, L. P., Yang, S., Shi, Q., Wang, Y., Qin, Y., Wang, J., & Li, Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-59173-6 · Cited by 6
Egbaria, A., Saliba, W., & Zafrir, B. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07107-5 · Cited by 6
Evaluation of Lipoprotein Profile and Residual Risk Three Years After Bariatric Surgery
Arnáiz, E. G., Ballesteros-Pomar, M. D., Roza, L. G., de la Maza, B. P., Bachiller, B. R., Cobo, D. A., Fondo, A. U., & Rodríguez, I. C. (2021) · Obesity Surgery · doi:10.1007/s11695-021-05543-2 · Cited by 6
Shi, B., Wang, H., Yin, D., Zhu, C., Feng, L., Wang, H., Jia, L., Fu, R., Song, C., Zhou, Z., et al. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9100342 · Cited by 7
Serum 25-hydroxyvitamin D3 is associated with homocysteine more than with apolipoprotein B
Kim, N.-K., Jung, M.-A., Choi, B. H., & Joo, N. (2022) · Nutrition Research and Practice · doi:10.4162/nrp.2022.16.6.745 · Cited by 6
Fonseca, A. F., Byrne, H., Laguna-Fernández, A., Itani, T., Studer, R. L., Heo, J., Dillon, A., Ferber, P. C., & Costa‐Scharplatz, M. (2023) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2023.29.5.519 · Cited by 6
Zhang, K., Wei, C., Shao, Y., Li, W., Zhao, Z., Song, Y., Tang, X., Li, Y., & Gou, Z. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e28155 · Cited by 7
Pinto, L. C. S., Mello, A. P. D. Q., Izar, M. C. D. O., Damasceno, N. R. T., Neto, A. M. F., França, C. N., Caixeta, A. M., Bianco, H. T., Póvoa, R., Moreira, F. T., et al. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01559-w · Cited by 6
Truscott, S. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815499-1.00006-5 · Cited by 6
Lin, Q., Fu, Y. H. H., Zang, X., Liu, Q., & Liu, L. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.686234 · Cited by 7
Nijssen, K. M. R., Chavez-Alfaro, M. A., Joris, P. J., Plat, J., & Mensink, R. P. (2024) · Nutrients · doi:10.3390/nu17010008 · Cited by 5
Langlois, M. R., & Briers, P.-J. (2021) · Biochemia Medica · doi:10.11613/bm.2022.010704 · Cited by 11
Self-citationSolnica, B., Sygitowicz, G., Sitkiewicz, D., Jozwiak, J. J., Kasperczyk, S., Broncel, M., Wolska, A. T., Odrowąż‐Sypniewska, G., & Banach, M. (2024) · Diagnostyka Laboratoryjna · doi:10.5604/01.3001.0054.4954 · Cited by 7
LDL Cholesterol: ‘The Times They Are A-Changin’
Chapman, M. J., Giral, P., & Thérond, P. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa110 · Cited by 5
Self-citationWu, H., Wang, C., Tuerhongjiang, G., Qiao, X., Hua, Y., She, J., & Yuan, Z. (2021) · Journal of Investigative Medicine · doi:10.1136/jim-2021-001803 · Cited by 5
Farjam, M., Kheirandish, M., Ghanbarnejad, A., Nikpoor, A. R., Nejatizadeh, A., Aghamolaei, T., Shahmoradi, M., Alizade, H., Homayounfar, R., Zarei, H., et al. (2024) · Archives of Iranian Medicine · doi:10.34172/aim.2024.03 · Cited by 5
Atherogenic Dyslipoproteinemia and Management of ASCVD
Watts, G. F., & Chan, D. C. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.03.032 · Cited by 5
Self-citationWhy Metrological Traceability Matters in Medical Laboratory Diagnostics
Lantman, M. V. S., Cobbaert, C., Panteghini, M., van Berkel, M. E. A. T., Smeets, R. L., van Hellemond, J. J., & Thelen, M. (2025) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfaf203 · Cited by 4
Self-citationNew joint consensus initiative on quantifying atherogenic lipoproteins
Stock, J. K. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.08.037 · Cited by 4
Kanda, D., Miyata, M., Ikeda, Y., Tokushige, A., Sonoda, T., Arikawa, R., Anzaki, K., Kosedo, I., Yoshino, S., Takumi, T., et al. (2021) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.62908 · Cited by 4
Nomikos, T., Georgoulis, M., Chrysohoou, C. A., Damigou, E., Barkas, F., Skoumas, I., Liberopoulos, E. N., Pitsavos, C. S., Tsioufis, C. P., Sfikakis, P. P., et al. (2023) · Lipids · doi:10.1002/lipd.12371 · Cited by 4
Labordiagnostik von Fettstoffwechselstörungen
März, W., Scharnagl, H., Kleber, M. E., Silbernagel, G., Nauck, M., Müller‐Wieland, D., & von Eckardstein, A. (2023) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1516-2511 · Cited by 5
Aldana, S. I., Demateis, D., Valvi, D., Just, A. C., Gutiérrez-Ávila, I., Estrada‐Gutiérrez, G., Téllez‐Rojo, M. M., Wright, R. O., Baccarelli, A., Wu, H., et al. (2024) · Environmental Research · doi:10.1016/j.envres.2025.121198 · Cited by 4
Li, C., He, K., Yang, Y., Li, K., Chen, M., Wang, L., Xu, X., & Li, W. (2023) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s389694 · Cited by 4
Logan, S. M., & Selvaratnam, R. (2023) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2023.110633 · Cited by 4
Velilla, T. A., Sánchez, G. V., García, I. R., Madrid, E. M., Sánchez, F. I. R., León‐Justel, A., Alguacil, B. G., Fontana, E. R., Herranz, M. L. D., Villegas, S. H., et al. (2021) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2020.12.009 · Cited by 5
Gaško, R. (2021) · Vnitřní lékařství · doi:10.36290/vnl.2021.028 · Cited by 4
Mora, S. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.016 · Cited by 4
Self-citationVargas‐Vázquez, A., Bello‐Chavolla, O. Y., Antonio‐Villa, N. E., Mehta, R., Aguilar-Salinas, C. A., & Cruz‐Bautista, I. (2021) · Research Square · doi:10.21203/rs.3.rs-249674/v2 · Cited by 4
Chabı, I. B., Akogou, F. U. G., Zannou, O., Atchadé, A. J., Adéyèmi, D. A., Alamri, A. S., Galanakis, C. M., & Kayodé, A. P. P. (2024) · Biomass Conversion and Biorefinery · doi:10.1007/s13399-024-05381-z · Cited by 3
Nutrients and bioactive compounds in nuts: implications for human health
Alasalvar, C., Salas‐Salvadó, J., Plaza‐Díaz, J., Ni, J., Sala‐Vila, A., Bolling, B. W., Salas‐Huetos, A., Mandalari, G., & Ros, E. (2026) · Food Chemistry · doi:10.1016/j.foodchem.2026.149828 · Cited by 4
Self-citationLee, M. J., Bae, J. H., Khang, A. R., Yi, D., Kim, J. Y., Kim, S. H., Kim, D. H., Kang, D., Park, S., Jeon, Y. K., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae632 · Cited by 3
Zambon, A., Gentile, L., Galimberti, F., Manzato, E., Giaccari, A., Sesti, G., Belfiore, A., Norata, G. D., Temporelli, P. L., Frulloni, L., et al. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104214 · Cited by 3
Self-citationPérez, S. M., Velilla, T. A., de la Iglesia, J. F., Rico, M. Á., Morales, C., & León‐Justel, A. (2022) · REC CardioClinics · doi:10.1016/j.rccl.2022.02.007 · Cited by 3
Lipoprotein(a) Elevation: A New Diagnostic Code with Relevance to Service Members and Veterans.
Engler, R. J. M., Brede, E., Villines, T. C., & Vernalis, M. (2019) · PubMed Central · Cited by 3
Armonizacion del estudio de lipidos en el laboratorio clinico
Lopez, G. I., & Schreier, L. E. (2019) · Redalyc (Universidad Autónoma del Estado de México) · Cited by 3
Sojit, T. O. M. O., Sankanagoudar, S., & SHUKLA, R. K. (2022) · Minerva Endocrinology · doi:10.23736/s2724-6507.22.03697-1 · Cited by 3
Investigations on the clinical utility of apolipoprotein B measurement: A research priority
Langlois, M. R. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319869578 · Cited by 4
Self-citationA new milestone on the road to global standardization of apolipoprotein measurements
Langlois, M. R. (2022) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2022-1117 · Cited by 3
Self-citationMeikle, T. G., Wu, J., Wang, T., Dakic, A., Yi, C., Mellett, N. A., van Buuren-Milne, M., Beyene, H. B., Cinel, M. A., Duong, T., et al. (2026) · Analytical Chemistry · doi:10.1021/acs.analchem.5c04984 · Cited by 2
Diederiks, N. M., Romijn, F. P. H. T. M., van Neer, N. J. M., Pieterse, M., Dittrich, J., Ceglarek, U., Cobbaert, C. M., Ruhaak, L. R., the IFCC Working Group for Standardization of Apolipoproteins by Mass Spectrometry, Ruhaak, L. R., et al. (2026) · Clinical Chemistry · doi:10.1093/clinchem/hvag041 · Cited by 2
Self-citationVelilla, T. A., Estruch, E. B., Garrido, J. R., Jiménez, M. R., Sánchez, G. M. V., & Rico, I. V. (2021) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2021.01.001 · Cited by 2
Prevalence of severe hypercholesterolemia observed in different hospitals in Andalusia and Ceuta
Velilla, T. A., Sánchez, G. V., García, I. R., Madrid, E. M., Sánchez, F. I. R., León‐Justel, A., Alguacil, B. G., Fontana, E. R., Herranz, M. L., Villegas, S. H., et al. (2021) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2021.07.008 · Cited by 2
Wong, W. K., Takeuchi, F., Thảo, L. T. P., Nicholls, S. J., Chew, D. P., & Peter, K. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf039 · Cited by 2
Whiss, P. A., Baldimtsi, E., & Wahlberg, J. (2025) · Physiological Reports · doi:10.14814/phy2.70282 · Cited by 2
Apolipoprotein B at the core: another step forward
Pirillo, A., & Catapano, A. L. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf572 · Cited by 2
Self-citationWang, W., Wang, Z., Zhao, Y., Wang, X., Li, H., & Zhang, Y. (2022) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13631 · Cited by 2
Solnica, B., Sygitowicz, G., Sitkiewicz, D., Cybulska, B., Jozwiak, J. J., Odrowąż‐Sypniewska, G., & Banach, M. (2020) · Diagnostyka Laboratoryjna · doi:10.5604/01.3001.0014.1296 · Cited by 2
Li, T., Zhang, Y., Xu, J., Wang, L., Zhang, F., & Cong, H. (2022) · Angiology · doi:10.1177/00033197221112134 · Cited by 2
Could the association between ozone and arterial stiffness be modified by fish oil supplementation?
Han, W., Zhang, J., Xu, Z., Yang, T., Huang, J., Beevers, S. D., Kelly, F. J., & Li, G. (2024) · Environmental Research · doi:10.1016/j.envres.2024.118354 · Cited by 2
CME-Labor 61: Neue Europäische Konsensus-Empfehlungen zur Dyslipidämie
von Eckardstein, A. (2020) · Praxis · doi:10.1024/1661-8157/a003437 · Cited by 2
A Contemporary Evaluation of Calculated and Directly Measured LDL
Lau, C. S., Loh, W. J., Phua, S. K., & Aw, T. C. (2021) · Japan Journal of Clinical & Medical Research · doi:10.47363/jjcmr/2021(1)109 · Cited by 1
Exploring the Novelty in Lipid Profiling of Patients: A Non-fasting Approach from Eastern India
Saharia, G. K., Nayak, S., Mahajan, P. B., & Mangaraj, M. (2022) · Journal of Laboratory Physicians · doi:10.1055/s-0042-1757410 · Cited by 1
Tybjærg‐Hansen, A., & Nordestgaard, B. G. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00004-2 · Cited by 1
Self-citationArshad, M. A., Iqbal, R., Raza, M., Bashir, R., Ahmed, T., & Parveen, A. (2023) · Gene · doi:10.1016/j.gene.2023.148052 · Cited by 1
Metadata
- Authors
- Langlois, M. R., Chapman, M. J., Cobbaert, C., Mora, S., Remaley, A. T., Ros, E., Watts, G. F., Borén, J., Baum, H., Bruckert, E., Catapano, A., Descamps, O. S., von Eckardstein, A., Kamstrup, P. R., Kolovou, G., Kronenberg, F., Langsted, A., Pulkki, K., Rifai, N., Sypniewska, G., Wiklund, O., Nordestgaard, B. G., & for the European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Joint Consensus Initiative
- Affiliations
- Ghent University (BE)
- Inserm (FR)
- Leiden University Medical Center (NL)
- Brigham and Women's Hospital (US)
- National Institutes of Health (US)
- Instituto de Salud Carlos III (ES)
- The University of Western Australia (AU)
- Sahlgrenska University Hospital (SE)
- Klinikum Ludwigsburg (DE)
- Pitié-Salpetriere University Hospital, Paris, France
- University of Milan (IT)
- Hôpital de Jolimont (BE)
- Institute for Clinical Chemistry, University Hospital Zurich, Zurich, Switzerland
- University of Copenhagen (DK)
- Onassis Cardiac Surgery Center (GR)
- Innsbruck Medical University (AT)
- University of Turku (FI)
- Boston Children's Hospital (US)
- Department of Laboratory Medicine, Collegium Medicum, NC University, Bydgoszcz, Poland
- Corresponding author
- Langlois, Michel R
- ORCID
- Venue
- Clinical Chemistry
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-07-01
- Volume
- 64
- Issue
- 7
- Pages
- 1006-1033
- ISSN
- 0009-9147 (ISSN-L)
- 1530-8561
- OpenAlex
- W2800713945
- Cited by
- 260
- References
- 146
- Citations by year
- 2026: 18 · 2025: 22 · 2024: 28 · 2023: 32 · 2022: 27 · 2021: 49 · 2020: 43 · 2019: 32 · 2018: 9
- FWCI
- 34.59
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Clinical Chemistry (publishedVersion)
- UWA Profiles and Research Repository (UWA) (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Leiden Repository (Leiden University) (submittedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- atherogenic lipoproteins, LDL cholesterol, non-HDL cholesterol, apolipoprotein B, LDL particle number, remnant cholesterol, lipoprotein(a), hypertriglyceridemia, cardiovascular risk prediction, treatment goals, cost-effectiveness, personalized medicine
- MeSH terms
- Humans, Cholesterol, LDL, Consensus, Atherosclerosis, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
